Tweet Group


Nov 16

Masks & PPE
Transmission
Immunity
Vaccines
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc.
First interim analysis included 95 participants with confirmed cases of COVID-19 Phase 3 study met statistical criteria with a vaccine efficacy of 94.5% (p
https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy
Natalie E. Dean, PhD @nataliexdean - Mon Nov 16
Another exciting Monday morning for COVID-19 vaccines! Moderna is reporting 94.5% efficacy for their mRNA vaccine. Read on for a biostatistician's breakdown of the interim results. 10 tweets on severe disease, subgroup analysis, and more. Press release: investors.modernatx.com/news-releases/… pic.twitter.com/56HGZhHXBk
540 1711 Open Tweet
9 expert retweets
Expert replies & quotes
Eric Topol @EricTopol - Mon Nov 16
Very exciting to see 94% efficacy of @moderna_tx #SARSCoV2 vaccine at interim analysis of 95 events. This replication of Pfizer's high efficacy tells us the virus is eminently vaccinatable. investors.modernatx.com/news-releases/…
391 1613 Open Tweet
4 expert retweets
Expert replies & quotes
Michael Mina @michaelmina_lab - Mon Nov 16
VACCINES can work! Another #COVID19 phase 3 vaccine trial reports awesome results. This time, an estimated 94% efficacy 95 COVID19 detected: only 5! in the vaccine group and 90 in the placebo But like Pfizer results - need to take w caution... WHY? 1/ investors.modernatx.com/news-releases/…
492 1748 Open Tweet
3 expert retweets
Expert replies & quotes
Kai Kupferschmidt @kakape - Mon Nov 16
Good vaccine news continues: @moderna_tx just announced its vaccine has shown 94,5% efficacy. In the study of more than 30,000 participants, 95 #covid19 cases were observed (starting two weeks after second dose): 90 in placebo group 5 in vaccine group buff.ly/3puVGK6
175 394 Open Tweet
2 expert retweets
Expert replies & quotes
Moderna @moderna_tx - Mon Nov 16
We just announced that mRNA-1273, our COVID-19 vaccine candidate, has met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study. Read more: buff.ly/3puVGK6 pic.twitter.com/YuLubU1tlx
2301 6954 Open Tweet
3 expert retweets
Beth S. Linas, PhD, MHS (she/her) @bethlinas - Mon Nov 16
When #epidemiologists say they’re interested in the data- not just the press release- this is what we mean👇There’s info on primary & secondary end points, demographics of those in the trial & those who became sick, & info on side effects #COVID19vaccine investors.modernatx.com/news-releases/…
28 109 Open Tweet
2 expert retweets
Expert replies & quotes
Ashish K. Jha @ashishkjha - Mon Nov 16
More good vaccine news. We could use it right now >90% efficacy of Moderna vaccine No severe cases in vaccine group (caveat: small numbers) Tolerable short-term side effects Diverse participants In these dark times, light end of tunnel got brighter investors.modernatx.com/news-releases/…
107 547 Open Tweet
Expert replies & quotes
Dr.Krutika Kuppalli @KrutikaKuppalli - Mon Nov 16
Questions I still have regarding the #Moderna #Vaccine #pressrelease - What was the efficacy in elderly patients (>65) and in those with chronic conditions? - Did patients in communities of color do the same? - How long is it protective? Press release investors.modernatx.com/news-releases/…
7 13 Open Tweet
Nsikan Akpan @MoNscience - Mon Nov 16
Moderna claims its #COVID19 mRNA vaccine is 95% effective via results from its first interim analysis. Let's unpack what they've presented... investors.modernatx.com/news-releases/…
74 151 Open Tweet
1 expert retweets
Antibiotic Steward🆔 Bassam Ghanem @ABsteward - Mon Nov 16
🔥🔥Breaking news🔥🔥 Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study Phase 3 study met statistical criteria with a vaccine efficacy of 94.5% @CarlosdelRio7 @InfectiousDz investors.modernatx.com/news-releases/…
24 49 Open Tweet
1 expert retweets
Dr. Angela Rasmussen @angie_rasmussen - Mon Nov 16
Another week started with good COVID-19 news: Moderna reports 94.5% efficacy in their interim data analysis from their phase 3 trial. investors.modernatx.com/news-releases/…
24 109 Open Tweet
Expert replies & quotes